Cartesian Therapeutics (Cartesian Therapeutics) Beginning Cash Position : $80.98 Mil (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Cartesian Therapeutics Beginning Cash Position?

Cartesian Therapeutics's Beginning Cash Position for the quarter that ended in Dec. 2023 was $80.98 Mil.

Cartesian Therapeutics's quarterly Beginning Cash Position declined from Jun. 2023 ($127.53 Mil) to Sep. 2023 ($115.00 Mil) and declined from Sep. 2023 ($115.00 Mil) to Dec. 2023 ($80.98 Mil).

Cartesian Therapeutics's annual Beginning Cash Position declined from Dec. 2021 ($140.06 Mil) to Dec. 2022 ($115.44 Mil) and declined from Dec. 2022 ($115.44 Mil) to Dec. 2023 ($108.04 Mil).

Cartesian Therapeutics Beginning Cash Position Historical Data

The historical data trend for Cartesian Therapeutics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cartesian Therapeutics Beginning Cash Position Chart

Cartesian Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Beginning Cash Position

Get a 7-Day Free Trial

37.68

91.55

140.06

115.44

108.04

Cartesian Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Beginning Cash Position	Get a 7-Day Free Trial															114.44	108.04	127.53	115.00	80.98

Cartesian Therapeutics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

Cartesian Therapeutics Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Cartesian Therapeutics's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Cartesian Therapeutics (Cartesian Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cartesian Therapeutics Inc (NAS:RNAC) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

1S7:Germany

Address

65 Grove Street, Watertown, MA, USA, 02472

Website

https://www.selectabio.com

Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. Its product pipeline includes MMA-101, SEL-212 for Chronic Severe Gout, SEL-313 for Ornithine Transcarbamylase Deficiency (OTC), and others.

Executives

Carsten Brunn	director, officer: President & CEO	C/O SELECTA BIOSCIENCES, INC., 480 ARSENAL WAY, WATERTOWN MA 02472
Peter G Traber	officer: Chief Medical Officer	430 THAMER LANE, HOUSTON TX 77025
Takashi Kei Kishimoto	officer: Chief Scientific Officer	480 ARSENAL ST., BUILDING ONE, WATERTOWN MA 02472
Lloyd P. Johnston	officer: COO and SVP, R&D	480 ARSENAL ST., BUILDING ONE, WATERTOWN MA 02472
Blaine Davis	officer: Chief Financial Officer	C/O ARTARA THERAPEUTICS, INC., 1 LITTLE WEST 12TH STREET, NEW YORK NY 10014
Carrie Smith Cox	director	SCHERING-PLOUGH CORPORATION, 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Timothy C Barabe	director	C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803
Timothy A Springer	director	36 WOODMAN ROAD, CHESTNUT HILL MA 02467
Kevin Tan	officer: Chief Financial Officer	20 HICKORY ROAD, WELLESLEY MA 02482
Nishan M Desilva	director	11119 NORTH TORREY PINES RD STE 200, LA JOLLA CA 92037
Ann K. Donohue	officer: VP Finance	C/O SELECTA BIOSCIENCES, INC., 480 ARSENAL WAY, BUILDING ONE, WATERTOWN MA 02472
Bradford D. Dahms	officer: Chief Financial Officer	C/O SELECTA BIOSCIENCES, INC., 480 ARSENAL WAY, WATERTOWN MA 02472
Goran Ando	director
Scott Dunseth Myers	director	C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121
Elona Esq. Kogan	officer: General Counsel	C/O SEER, INC., 3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065